Discussing the Latest in MS Treatment and Disease-Modifying Therapies
Charles Turck, PharmD, BCPS, BCCCP
Jay Avasarala, MD, PhD
Highlights from the 2023 Psych Congress
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Craig Chepke, MD, FAPA
A New Hope for Patients with MS – The First FDA-Approved Biosimilar
The Hidden Struggles of Tardive Dyskinesia: Improving Patient Care
Studying the Safety of Discontinuing DMTs in MS Older Adults
Andrew Wilner, MD, FACP, FAAN
John Corboy, MD, MA
The Great Debate Surrounding Dietary Sodium: The Peril of Applying Population Statistics to Individual Patients
Michael J. Thorpy, MD
Franz H. Messerli, MD
BID Oxybate to QHS: What Clinicians and Patients Need to Know
Clete A. Kushida, MD, PhD
Oxybates: 1 Molecule, 3 Formulations – Safety
Oxybates: 1 Molecule, 3 Formulations – Efficacy
The Etiology of CV Issues in Patients with Narcolepsy
Disrupted Nighttime Sleep: A Long-Night’s Journey Into Day
Anne Marie Morse, DO
Can We Talk? Optimizing Patient Buy-In to the Management of Narcolepsy
Clarity for Schizophrenia: The Latest in Drug Treatment
Locked Up in My Own Mind: Challenges in the Criminal Justice System
New Drug Approved for PPD: Solving an Unmet Need
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease – Neurology Module
James Galvin, MD, MPH, FANA
Jon Toledo, MD, PhD
Supporting the Peripartum Period Through Perinatal Psychiatry
Nichelle Haynes, DO
Cardiovascular Effects of Oxybate: A 20-Year Safety Record
Narcolepsy 1 and 2: Recognizing Symptoms Including Excessive Sleepiness and Cataplexy
Sodium Oxybate: A Standard of Care for the Management of Narcolepsy for 20 Years
Loading...
Stay current with the best on medical education
We’re glad to see you’re enjoying Global Neurology Academy…but how about a more personalized experience?
Press cancel to remain on Global Neurology Academy. Press the link below or the continue button to keep going.